Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer

REFERENCES

• Papetti M., Herman I. M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. 2002; 282: 947–970
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990; 82: 4–6
   PubMed Web of Science ®Google Scholar
• Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997; 18: 4–25
   PubMed Web of Science ®Google Scholar
• Sanger D. R., Claffey K. P., Benes J. E., Perruzzi C. A., Sergiou A. P., Detmar M. Angiogenesis promoted by vascular endothelial growth factor: Regulation through α1β1 and α2β1 integrins. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 13612–13617
   PubMed Web of Science ®Google Scholar
• Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 1995; 146: 1029–1039
   PubMed Web of Science ®Google Scholar
• Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing. Mol. Endocrinol. 1991; 5: 1806–1814
   PubMed Web of Science ®Google Scholar
• Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60: 202–212
   Google Scholar
• Robinson C. J., Stringer S. E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001; 114: 853–865
   PubMed Web of Science ®Google Scholar
• Neufeld G., Cohen T., Gengrinovitch P., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9–22
   PubMed Web of Science ®Google Scholar
• De Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–991
   PubMed Web of Science ®Google Scholar
• Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992; 187: 1579–1586
   PubMed Web of Science ®Google Scholar
• Senger D. R., Perruzzi C. A., Feder J., Dvorak H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986; 46: 5629–5632
   PubMed Web of Science ®Google Scholar
• Foekens J. A., Peters H. A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61: 5407–5414
   PubMed Web of Science ®Google Scholar
• Fuckar D., Dekanic A., Stifter S., Mustac E., et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int. J. Surg. Pathol. 2006; 14: 49–55
   PubMed Web of Science ®Google Scholar
• Yoshiji H., Gomez D. E., Shibuya M., Thorgeirsson U. P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996; 56: 2013–2016
   PubMed Web of Science ®Google Scholar
• Anan K., Morisaki T., Katano M., Ikubo A., et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333–339
   PubMed Web of Science ®Google Scholar
• Brown L. F., Berse B., Jackman R. W., Tognazzi K., et al. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 1995; 26: 86–91
   PubMed Web of Science ®Google Scholar
• Lee A. H. S., Dublin E. A., Bobrow L. G., Poulsom R. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J. Pathol. 1998; 185: 394–401
   PubMed Web of Science ®Google Scholar
• Anan K., Morisaki T., Katano M., Ikubo A., et al. Preoperative assessment of tumor angiogenesis by vascular endothelial growth factor mRNA expression in homogenate samples of breast carcinoma: fine-needle aspirates vs. resection samples. J. Surg. Oncol. 1997; 66: 257–263
   PubMed Web of Science ®Google Scholar
• Anan K., Morisaki T., Katano M., Ikubo M., et al. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: Pre-operative determination of malignant potential. Eur. J. Surg. Oncol. 1998; 24: 28–33
   PubMedGoogle Scholar
• Guidi A. J., Schnitt S. J., Fischer L., Tognazzi K., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1996; 80: 1945–1953
   Web of Science ®Google Scholar
• Eppenberger U., Kueng W., Schlaeppi J. M., Roesel J. L., et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 1998; 16: 3129–3136
   PubMed Web of Science ®Google Scholar
• Gasparini G., Toi M., Gion M., Verderio P., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997; 89: 139–147
   PubMed Web of Science ®Google Scholar
• Linderholm B., Tavelin B., Grankvist K., Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 1998; 16: 3121–3128
   PubMed Web of Science ®Google Scholar
• Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta 1994; 1221: 211–214
   PubMed Web of Science ®Google Scholar
• Salven P., Maenpaa H., Orpana A., Alitalo K., Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 1996; 3: 647–651
   Web of Science ®Google Scholar
• Kraft A., Weindel K., Ochs A., Marth C., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1996; 85: 178–187
   Google Scholar
• Yamamoto Y., Toi M., Kondo S., Matsumoto T., et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res. 1996; 2: 821–826
   PubMed Web of Science ®Google Scholar
• Salven P., Perhoniemi V., Tykka H., Maenpaa H., Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res. Treat. 1999; 53: 161–166
   PubMed Web of Science ®Google Scholar
• Heer K., Kumar H., Read J. R., Fox J. N., Monnson J. R., Kerin J. M. Serum Vascular Endothelial Growth Factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin. Cancer Res. 2001; 7: 3491–3494
   PubMed Web of Science ®Google Scholar
• Hyder S M. Sex steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer 1996; 13: 667–687
   Google Scholar
• Webb N. J., Bottomley M. J., Watson C. J., Brenchley P. E. C. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease. Clin. Sci. 1998; 94: 395–404
   PubMed Web of Science ®Google Scholar
• O'Byrne K. J., Dobbs N., Propper D., Smith K., Harris A. L. Vascular endothelial growth factor platelet counts and prognosis in renal cancer. Lancet 1999; 353: 1494–1495
   PubMed Web of Science ®Google Scholar
• Curigliano G., Petit J. Y., Bertolini F., Colleoni M., et al. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor(VEGF) and transforming growth factor beta (TGF-β) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res. Treat. 2005; 93: 35–40
   PubMed Web of Science ®Google Scholar
• Fuckar D., Dekanic A., Stifter S., Mustac E., et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer
   Google Scholar
• Foekens J. A., Peters H. A., Grebenchtchikov N., Look M. P., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61: 5407–5414
   PubMed Web of Science ®Google Scholar
• Rydén L., Jirstrom K., Bendhal P. O., Ferno M., et al. Tumor specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J. Clin. Oncol. 2005; 23: 4695–4704
   PubMed Web of Science ®Google Scholar
• Toi M., Matsumoto T., Bando M. Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications. Lancet Oncol. 2001; 2: 667–673
   PubMed Web of Science ®Google Scholar
• Van Meier E. G., Polverini P. J., Chazin V. R., et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994; 8: 171–176
   PubMed Web of Science ®Google Scholar
• Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutation in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9: 1595–1602
   PubMed Web of Science ®Google Scholar
• Nishimura R., Nagao K., Miyayama H., Matsuda M., et al. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53 and recurrence of breast cancer. Breast Cancer 2003; 10: 120–128
   PubMedGoogle Scholar
• Berns E.M. J.J., Klijn G. M. J., Look M. P., Grebenchtchikov N, et al. Combined vascular endothelial growth factor and p53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin. Cancer Res. 2003; 9: 1253–1258
   PubMed Web of Science ®Google Scholar
• Liang Y., Wu J., Hyder S. M. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2005; 93: 173–182
   PubMed Web of Science ®Google Scholar